Hydrogen Cyanide and Enzymes

The studies of American biochemist Ernst T. Krebs, Jr, DSc, from the late 1940s, and many others through to the present who have duplicated his findings, show that vitamin B17 is in the cyanide family, but it is good cyanide.

It is two parts glucose, one part hydrogen cyanide and one part benzaldehyde (an analgesic).

Hydrogen cyanide is non-toxic when taken as a food or in controlled doses as a refined pharmaceutical. Commonly consumed substances such as salt and sugar can be up to 20 times more toxic.

Krebs claimed that the body breaks down B17 using the enzyme rhodanese, which changes it into thiocyanate and benzoic acid. These are beneficial,, working with B 12 to nourish the body. Excesses of these by-products are expelled from the body via urine.

Krebs’s work demonstrated that rhodanese has an inverse relationship to cancer cells: it is found everywhere in a normal healthy body, but not where cancer cells exist.

However, the enzyme beta­glucosidase has a direct relationship to cancer cells and is found in very large quantities around them. If there is no cancer in the body, there is no beta-glucosidase enzyme.

However, when B17 comes into contact with beta -gl ucos idase that is present in large quantities around colonies of cancer cells, a chemical reaction occurs and the hydrogen cyanide and benzaldehyde combine to produce a poison which destroys only cancer cells.

This process is known as selective toxicity. (See diagram.)




Why does one substance, Laetrile, appear to be selectively toxic against most cancers when there are hundreds of different kinds?

Ernst T. Krebs, Jr, an honorary Doctor of Science, found that the only constant, the malignant or neoplastic component in all exhibitions of cancer, is susceptible to the Laetrile reaction’s specific toxicity.

This is the trophoblast.

Trophoblast cells are primitive cells that have a fierce antithesis to all other cell types, including their somatic or hostal cells.

Krebs (1993) wrote: “Cancer is trophoblast in spatial and temporal anomaly, hybridised with and vascularized by hostal or somatic cells and in irreversible and fiercely malignant antithesis to such.”

So, we are looking at any specialist cell that mutates into a typical, less evolved and more aggressive form. B17/Laetrile is thus a typical treatment fora typical cell type.